Trial · NCT05324423
To Evaluate Drug Interactions Between XNW3009, Febuxostat, and Colchicine in Patients With Gout
NCT05324423, Phase 1, Unknown, The Affiliated Hospital of Qingdao University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. To Evaluate Drug Interactions Between XNW3009, Febuxostat, and Colchicine in Patients With Gout. Trials, record NCT05324423. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05324423
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- To Evaluate Drug Interactions Between XNW3009, Febuxostat, and Colchicine in Patients With Gout
- NCT number
- NCT05324423
- Status
- Unknown
- Phases
- Phase 1
- Enrollment
- 20 participants, estimated
- Lead sponsor
- The Affiliated Hospital of Qingdao University
- Conditions
- Gout
- Interventions
- Colchicine
- First posted
- 2022-04-12
- Last updated
- 2022-05-09
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Observed maximum concentration at steady state (Cmax,ss) | 100 days | To evaluate the maximum concentration at steady state of oral XNW3009 tablets, febuxostat, and colchicine in patients with gout |
| Primary | Observed area under the concentration-time curve from zero to the end of the dosing interval at steady state (AUCss) | 100 days | To evaluate the AUCss of oral XNW3009 tablets, febuxostat, and colchicine in patients with gout |
| Secondary | Time to Maximum Serum Concentration (Tmax) | 100 days | To evaluate the Tmax of oral XNW3009 tablets, febuxostat and colchicine in patients with gout |
| Secondary | Mean Terminal Phase Half-life (t1/2) | 100 days | To evaluate the t1/2 of XNW3009 tablets, febuxostat and colchicine in gout patients |
| Secondary | Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) | 100 days | Data for number of participants who presented one or more adverse events (serious or non serious) was reported. An AE was defined as any untoward medical occurrence (MO) in a participant temporally associated with the use of a medicinal product (MP), whether or not considered related to the MP and can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with its use. The SAE was any untoward MO that, at any dose, results in death, life threatening, persistent or significant disability/incapacity, results in or prolongs inpatient hospitalization, congenital abnormality or birth defect, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition. |
| Secondary | Serum or urine Uric Acid Level | 100 days | Change in Serum or urine Uric Acid Level |
| Secondary | Serum or urine Creatinine | 100 days | Change in Serum or urine Creatinine |
| Secondary | Number of Participants With Clinically Significant Laboratory Test Abnormalities | 100 days | Investigator judged clinical significance of laboratory test abnormalities. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05324423
GET https://conductscience.org/api/trials/v1/NCT05324423/registered